Related Experiment Video

Updated: May 31, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

No influence on disease progression of non-HLA susceptibility genes in MS

Wangko Lundström1, Eva Greiner, Frida Lundmark

  • 1The Multiple Sclerosis Research group, Centre for Molecular Medicine, Department of Clinical neuroscience, Karolinska Institutet, Stockholm, Sweden. wangko.lundstrom@ki.se

Journal of Neuroimmunology
|July 12, 2011
PubMed

Insights

Genetic variations linked to Multiple Sclerosis (MS) susceptibility do not appear to influence disease progression. Five non-HLA genotypes, including IL7R and CLEC16A, were studied in Scandinavian MS patients, showing no correlation with outcome measures.

Area of Science:

  • Immunogenetics
  • Neuroimmunology
  • Genetics of autoimmune diseases

Background:

  • Multiple Sclerosis (MS) is an autoimmune disease impacting the central nervous system.
  • Several non-Human Leukocyte Antigen (non-HLA) genetic loci are associated with MS susceptibility.
  • These susceptibility genes are presumed to play a role in MS pathogenesis.

Purpose of the Study:

  • To investigate whether non-HLA genotypes associated with MS susceptibility also influence disease progression.
  • To determine if genetic variations in specific genes (IL7R, IL2RA, CLEC16A, CD226, SH2B3) impact clinical outcomes in MS patients.
  • To explore the dissociation between genetic predisposition and disease severity in Multiple Sclerosis.

Main Methods:

  • Genotyping of five non-HLA loci (IL7R, IL2RA, CLEC16A, CD226, SH2B3) in a cohort of 1776 Scandinavian Multiple Sclerosis patients.
  • Analysis of genotype data in relation to established disease outcome measures.
  • Statistical assessment to identify any correlation between specific genotypes and disease progression.

Main Results:

  • A consistent dissociation was observed between the susceptibility-associated genotypes and disease progression in Multiple Sclerosis.
  • The five investigated non-HLA genotypes (IL7R, IL2RA, CLEC16A, CD226, SH2B3) did not show a significant influence on disease outcome measures.
  • This suggests that genetic factors contributing to MS risk may not directly drive ongoing tissue damage or disease severity.

Conclusions:

  • Genetic susceptibility to Multiple Sclerosis, as indicated by non-HLA loci, does not necessarily predict disease progression.
  • The pathways implicated by these susceptibility genes may be more critical for initiating the disease rather than determining its clinical course.
  • Further research is needed to understand the distinct roles of genetic factors in MS initiation versus progression.

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Mismatch Repair01:20

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...